Celyad Oncology SA (CYAD.BR)
- Previous Close
0.3150 - Open
0.3155 - Bid --
- Ask --
- Day's Range
0.3150 - 0.3390 - 52 Week Range
0.2975 - 1.2800 - Volume
17,101 - Avg. Volume
21,001 - Market Cap (intraday)
13.879M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3600 - Earnings Date May 3, 2024 - May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; Multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery / PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
www.celyad.comRecent News: CYAD.BR
Performance Overview: CYAD.BR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYAD.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYAD.BR
Valuation Measures
Market Cap
13.05M
Enterprise Value
8.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
161.50
Price/Book (mrq)
12.81
Enterprise Value/Revenue
195.68
Enterprise Value/EBITDA
-0.28
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.03%
Return on Equity (ttm)
-159.08%
Revenue (ttm)
102k
Net Income Avi to Common (ttm)
-8.45M
Diluted EPS (ttm)
-1.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
7M
Total Debt/Equity (mrq)
16.78%
Levered Free Cash Flow (ttm)
-14.45M
Research Analysis: CYAD.BR
Company Insights: CYAD.BR
CYAD.BR does not have Company Insights